London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Exactly three years ago there were strong rumours that Mylan was preparing to make a £7 Billion plus bid (£35.00 per share) for Hikma. Now we are sitting at £8.50 per share for no good reason except the Advair Generic being delayed. You couldn't make it up.
I know the feeling and share your pain aamir,the news that Novartis are having trouble getting Advair generic past FDA has not helped our cause, never thought the market would punish us so hard, just got to let this play out now and take a 3 year view,GLA.
this looks very bad. its under 886p major support level..next support at 765p then 726p. take your pick.
It's seems I am in a business which turning Grace to Ugly shape.... Wish could never kept average down on early.
The FDA's favouritism towards Glaxo knows no bounds. Let's hope someone blows the whistle on them.
Thank you Pianista and Soniraman. That makes more sense than Directors selling at a ridiculously low price and the message that would have sent out. The fall today must be solely due to FDA rejecting another Advair application this time from Novartis. That's three Pharmaceutical companies with the most modern manufacturing plants and skilled chemists that are unable to gain approval for a generic version of a drug that has been on the market for over 15 years. You could perhaps understand one or two (at a push) failing at the final hurdle but there's definitely something not right when three are rejected. FDA had better be sure they are not being pressurised into these decisions or they open themselves up to legal action.
It seems that the shares were pledged to Arab bank and another bank.. These were released and pledged to MS.. sort of status quo
My reading of the RNS's is that these weren't sales or purchases at all, rather the making/ releasing of pledges to various banks of existing shareholdings. So not much significance, if any, IMHO.
Vectura Group Plc is uncertain whether revenue from its generic version of Advair will come in 2018, 2019 or 2020, after a delay in U.S. approval last year, CEO James Ward-Lilley said in an interview last month. Glaxo�s drug is forecast by analysts to generate about 2.2 billion pounds ($3.1 billion) in sales this year, according to data compiled by Bloomberg. U.K.-based Vectura and partner Hikma Pharmaceuticals Plc remain confident that their application will be approved �in due course,� a Vectura spokesman said. Shares of Novartis were down 0.5 percent at 11:32 a.m. after slipping as much as 1 percent in Zurich trading.
This seems a depressing situation for shareholders...:( Hope its not and this Advair stuff should not life or death for Hikma.
News is coming through that the FDA have also denied the Novartis Advair Generic application. You would think that this would boost Hikma (less competition) but the other way of looking at it is that the FDA are playing hardball with this Generic and this may scupper Hikmas appeal. If the Director Dealing is them actually offloading shares then it means two things 1/ They are not exactly confident that things will improve in the near future and 2/ They will not be hard to deal with if any company wishes to take them over.
Can anyone shed some light on the recent Director Share dealings. As usual, it's really difficult to tell if they have bought them or sold them. We are talking about big amounts 6M, 2M and by several Directors.
Should be Motto in case any of you wish to Google him.
Good day today, sincerely hope it is the start of a revival in the SP but I'm not building up my hopes too much. I'm registered to receive updates from Hikma and they have just confirmed the appointment of Daniel Moto who joins Hikma from Teva. His job title is Executive Vice President of US injectables. He has a wealth of experience and he will strengthen that side of the business (injectables)--time will tell of course but at least Hikma seem to be addressing matters with this appointment and that of a new chief Scientist a Couple of weeks ago.
I am half expecting five weeks of 'recovery' from here before the results in mid March.
Dropped this morning to 895p, but recovered in a very poor market...so...there are always those out there who know these are cheap
Jimbo1122, yeah..i agree with you ...plenty going on despite the current headwinds "Roxane has a strong pipeline of 89 projects in various stages of development, including 32 products which are currently filed with the FDA and 57 Paragraph IV products, and a consistent track-record of delivering new products to market " http://www.hikma.com/en/media/news-and-press-releases/corporate-news/2015/hikma-acquires-roxane-laboratories--transforming-its-position-in.html There is also the update to the ANDA for generic Advair Diskus� Clinical Endpoint (CEP) study, dispute resolution process, with the FCA .. due by the end of Q1 http://www.vectura.com/news/hikma-trading-update-statement-its-anda-generic-advair-diskus-vr315/ Th Hikma corporate venture capital arm is something I dont know too much about... http://www.hikmaventures.com/en/about-us.html
Pokerchips - - you're right about 2018 continuing to be difficult but Hikma also state that in 2018 there will be " an acceleration in product launches, including two date certain launches". 2019 - - Hikma expect market conditions to improve plus they have a strong pipeline " to drive growth" There will be additional respiratory launch opportunities, multiple and significant PIV opportunities and also M&A upside potential. Recently, Hikma signed agreements with several pharmaceutical companies and a new chief Scientist with a proven track record recently joined the company. Hikma must now be a takeover candidate which would be great for the shareholders but if Hikma are left to their own devices then the SP will surely recover over time.
What are your views on a mid-long term? Are two years consider enough for the mid-long term?
the City seems most interested in Earnings Per Share and that is under pressure at the moment largely because of the Generics Division price and volume falls.. There is also talk that they may write down the value of the Roxane Laboratories Generics Company assets they bought in 2015 and paid US$2.65 billion (cash and shares) which havent as yet performed sufficiently well. They did say that they thought the generics problems would continue in 2018 so maybe the market bekieves the situation will get worse before it gets better...remains to be seen... Clearly you have to take a mid-long term view on the whole thing
It is ridiculous. Hikma is now valued at less than their asset value and they are making profits (not losses). There are many true basket cases in the Ftse 100/250 that are making losses with no prospects of recovery but they are valued much higher than Hikma. Hikma has a strong balance sheet, easily manageable debts and have are highly cash generative. Hikma are also fortunate in that they are in a sector that always has new avenues to capitalise on. A few new (exclusive) drugs and they are back on the road to recovery. Seriously, if i wasn't so heavily invested in Hikma at the moment i would definitely buy in big time as there is now far more upside than downside. For what it's worth, Peel Hunt reiterated a buy with a target price of 1390p (1/2/18). Funny how the fund managers ignored that but the SP fell over 6% when Jeffries had a sell notice with a target of 895p just recently.
I check in here from time to time and am gobsmacked how the share price has been worked down and kept there. insane. does someone know something that damaging out there?
It's not roller caster any more as mostly its close low. I agree that Hikma fundamentals are strong and diversified business in three categories make it sustainable in difficult times but seems market hate this SP for a while as it's comparatively more low than any other pharma on ftse. Let see if USA NHS development brings any positivity.
Someone sold £260,000 worth of Shares at 8.00am this morning which caused a huge dip in SP but fortunately it seems that these shares have been eagerly snapped up and the SP has recovered but still down as i post this. I look forward to the day when the City suddenly realises that this is now a bargain stock and act accordingly.